Molbio Diagnostics Ltd.

•

molbiodiagnostics.comBSE: -NSE: MOLBIO

Market Cap₹ 14,498 Cr.

Current Price

High / Low₹ 1,294 / 926

Stock P/E100.2

Book Value₹ 121

Price to Book12.50

Dividend Yield0.00 %

ROCE17.8 %

ROE13.6 %

Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Operating margins have improved to 18.8% from 12.3%
Company comfortably covers its interest (9.5x coverage)
Company generates healthy free cash flow
Company maintains a comfortable, low leverage position
Attractively priced for its growth - PEG of 0.9

CONS

Operating cash flow has been negative in recent years
Receivables are growing faster than sales - a possible quality concern
Total debt has risen sharply - up 1821.9% year on year
Equity base is being diluted - shares outstanding up 400.3%
Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcareMedical Equipment/Supplies/Accessories

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	LENSKART	694.05	184.20	120716.54	0.00	2284.30	3634.35	27141.80	1332.69	12.55	21.70
2.	POLYMED	1723.80	55.45	17472.69	0.20	85.27	-8.39	525.38	30.30	14.05	24.11
3.	MOLBIO	1258.10	87.03	14498.34	0.00	527.44	—	4083.76	—	19.79	24.63
4.	3BBLACKBIO	1472.10	22.75	1263.45	0.34	8.98	-28.99	33.49	50.59	26.03	25.45
5.	LAXMIDENTL	200.40	35.70	1102.79	0.00	10.32	23.83	74.70	16.13	24.96	20.26
6.	GKB	66.13	10.28	33.33	0.00	1.85	387.99	33.04	2.26	8.82	7.97

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2025	Jun 2026
	95	3,994
	114	3,248
Operating Profit	-19	746
OPM %	-19.87%	18.67%
	1	14
Interest	2	87
Depreciation	7	84
Profit before Tax	-17	759
Tax %	23.23%	25.42%
Net Profit	-13	566
	-1.19	5.02

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	327	756	971	1,313
	286	553	746	1,062
Operating Profit	40	204	226	252
OPM %	12.27%	26.93%	23.23%	19.18%
	8	-21	-2	5
Interest	6	8	9	23
Depreciation	19	24	26	36
Profit before Tax	23	152	188	198
Tax %	31.98%	26.85%	25.64%	26.79%
Net Profit	16	111	140	145
EPS	68.97	492.93	61.98	12.83
Dividend Payout %	0.00%	0.00%	0.00%	0.00%

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: 59%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: 110%

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: —
1 Year:: —

RETURN ON EQUITY

10 Years:: —
5 Years:: —
3 Years:: 14%
Last Year:: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	2	11
	736	847	988	1,123
	54	58	12	322
Trade Payables	75	96	235	180
	46	50	29	56
Total Liabilities	913	1,054	1,266	1,692
	189	176	215	257
Capital Work in Progress	0	2	18	6
	54	54	95	317
	328	293	410	397
	173	360	228	359
Cash & Bank	5	18	111	109
	165	152	190	248
Total Assets	913	1,054	1,266	1,692

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	68	38	249	-38
Cash from Investing	-51	-31	-98	-256
Cash from Financing	31	-24	-17	292
	48	-18	133	-2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Aug 2026
	41.29
	1.51
	16.36
Government	0.00
	40.82

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-09

Updates

2026-09-09 - Molbio Diagnostics Limited has informed the Exchange regarding Intimation regarding change of Corporate Identification Number (CIN) of the Company.

2026-09-08

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-08 - Molbio Diagnostics Limited has informed the Exchange about Link of Recording

2026-09-08

General Updates

2026-09-08 - Molbio Diagnostics Limited has informed the Exchange about Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026

2026-09-07

Copy of Newspaper Publication

2026-09-07 - Molbio Diagnostics Limited has informed the Exchange about Copy of Newspaper Publication of Un-audited Financial Results for the quarter ended June 30, 2026.

2026-09-07

Press Release

2026-09-07 - Molbio Diagnostics Limited has informed the Exchange regarding a press release dated September 07, 2026, titled "Press Release for the Quarter ended June 30, 2026.".

2026-09-05

Outcome of Board Meeting

2026-09-05 - Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-09-02

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-02 - Molbio Diagnostics Limited has informed the Exchange that an Earnings Conference Call is scheduled on Tuesday, 08th September 2026 at 04.00 P.M. IST to discuss the financial performance of the Company for the quarter ended June 30, 2026.

2026-08-27

Outcome of Board Meeting

2026-08-27 - Molbio Diagnostics Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026.

2026-08-20

Trading Window

2026-08-20 - Molbio Diagnostics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

News

Recent coverage and analyst commentary for MOLBIO

Loading news…

🤖

AI Stock Analyst

Molbio Diagnostics Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

LENSKART

694.05

184.20

120716.54

0.00

2284.30

3634.35

27141.80

1332.69

12.55

21.70

POLYMED

1723.80

55.45

17472.69

0.20

85.27

-8.39

525.38

30.30

14.05

24.11

MOLBIO

1258.10

87.03

14498.34

0.00

527.44

—

4083.76

—

19.79

24.63

3BBLACKBIO

1472.10

22.75

1263.45

0.34

8.98

-28.99

33.49

50.59

26.03

25.45

LAXMIDENTL

200.40

35.70

1102.79

0.00

10.32

23.83

74.70

16.13

24.96

20.26

GKB

66.13

10.28

33.33

0.00

1.85

387.99

33.04

2.26

8.82

7.97

Jun 2025

Jun 2026

3,994

114

3,248

Operating Profit

-19

746

OPM %

-19.87%

18.67%

Interest

Depreciation

Profit before Tax

-17

759

Tax %

23.23%

25.42%

Net Profit

-13

566

-1.19

5.02

Mar 2023

Mar 2024

Mar 2025

Mar 2026

327

756

971

1,313

286

553

746

1,062

Operating Profit

204

226

252

OPM %

12.27%

26.93%

23.23%

19.18%

-21

-2

Interest

Depreciation

Profit before Tax

152

188

198

Tax %

31.98%

26.85%

25.64%

26.79%

Net Profit

111

140

145

EPS

68.97

492.93

61.98

12.83

Dividend Payout %

0.00%

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity Capital

736

847

988

1,123

322

Trade Payables

235

180

Total Liabilities

913

1,054

1,266

1,692

189

176

215

257

Capital Work in Progress

317

328

293

410

397

173

360

228

359

Cash & Bank

111

109

165

152

190

248

Total Assets

913

1,054

1,266

1,692

Mar 2023

Mar 2024

Mar 2025

Mar 2026

249

-38

Cash from Investing

-51

-31

-98

-256

Cash from Financing

-24

-17

292

-18

133

-2

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Aug 2026

41.29

1.51

16.36

Government

0.00

40.82

Molbio Diagnostics Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Molbio Diagnostics Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI